Capital securities issued a research report on January 29, giving a buy rating of Betta Pharmaceuticals Co.Ltd(300558) (300558.sz, latest price: 62.3 yuan). The reasons for rating mainly include: 1) the performance of the whole year increased steadily, and the amount of ensatinib was large; 2) The negotiation on medical insurance is progressing smoothly, and the approval of new products opens up room for growth; 3) R & D investment continues to increase, and the pipeline under research is arranged in many aspects around the tumor field. Risk tips: risk of R & D failure, product sales falling short of expectations, centralized purchase or medical insurance negotiation price reduction exceeding expectations.
AI comments: Betta Pharmaceuticals Co.Ltd(300558) has received attention from 4 research reports of securities companies in recent month and bought 2.
